Jinan Jianfeng Chemical CO., ltd

Dermorphin Peptide powder cas 77614-16-5

For a number of years, we have been quite interested in the repositioning of old drugs, especially subsequent to finding topical phenytoin, ketamine, baclofen, and loperamide effective in alleviating neuropathic pain. We have since concentrated on the repositioning of an old molecule, phenytoin, forgotten as an analgesic. We found phenytoin to be quite valuable for the treatment of localized peripheral neuropathic pain, for conditions including painful diabetic neuropathy, chemotherapy induced neuropathy, small fiber neuropathy, and chronic idiopathic axonal neuropathy.3 The clinical effects of this old molecule, first synthesized in the beginning of the 20th century, provoked us to search for other “forgotten molecules” useful in in the field of chronic pain. This was particularly relevant, as many pharmaceutical companies withdrew their research activities from this field over the past decade. In our investigation, the case of dermorphin arose once again.

Dermorphin has a high affinity and selectivity for µ-opioid receptors: Its opioid potency in guinea pig ileum (GPI) preparations is 100 times higher than that of morphine. The amidated analogs of Ph. bicolor dermorphins display a similar or slightly higher µ-opioid receptor affinity but a significantly higher (15–20 times) κ-opioid receptor affinity than dermorphin does (Table 2).